Asia is the center of gravity for global patent activity. The five IP offices that make up the IP5 -- the USPTO, EPO, Japan Patent Office (JPO), Korean Intellectual Property Office (KIPO), and China National Intellectual Property Administration (CNIPA) -- collectively handle approximately 85% of the world's patent applications, and three of those five are in Asia. China alone receives more patent applications each year than any other country on earth -- more than the United States and Europe combined. Japan and South Korea are home to some of the world's most prolific patent filers. India is the fastest-growing major patent jurisdiction. And Taiwan, though not a member of the PCT or WIPO, operates a sophisticated patent system critical to the global semiconductor industry.
This chapter covers the five most important Asian patent jurisdictions: China (CNIPA), Japan (JPO), South Korea (KIPO), India (IPO), and Taiwan (TIPO). For each, you will learn the key features of the patent system, the types of protection available, the examination timeline, and the strategic considerations that should inform your filing decisions.
Why Asia Matters for Patent Strategy
IP5 Patent Filing Share
| Office | Country | Approximate Annual Filings (2024) | Share of Global Total |
|---|---|---|---|
| CNIPA | China | 1,640,000 | ~46% |
| USPTO | United States | 620,000 | ~17% |
| JPO | Japan | 300,000 | ~8% |
| KIPO | South Korea | 290,000 | ~8% |
| EPO | Europe (39 states) | 200,000 | ~6% |
| IPO | India | 90,000+ | ~3% |
| TIPO | Taiwan | 75,000+ | ~2% |
Three factors drive the strategic importance of Asian patent filings. First, these are massive consumer and manufacturing markets -- if your products are made in, sold in, or shipped through these countries, you need patent protection to prevent copying and preserve licensing revenue. Second, Asian patent offices have substantially improved examination quality and enforcement mechanisms over the past two decades, making granted patents genuinely valuable rights. Third, companies headquartered in these countries are filing aggressively, both at home and abroad. Understanding their patent systems helps you anticipate competitive threats and design an effective portfolio.
China (CNIPA)
The China National Intellectual Property Administration (CNIPA, formerly SIPO) is the world's largest patent office by filing volume. Chinese patent documents became part of the PCT minimum documentation on 1 July 2012, reflecting their growing importance as global prior art.
Three Types of Patent Protection
China offers three distinct types of patent protection, each with different requirements, procedures, and strategic uses:
| Feature | Invention Patent | Utility Model | Design Patent |
|---|---|---|---|
| Subject matter | Products and processes | Shape/structure of products | Aesthetic design of products |
| Substantive examination | Yes (mandatory) | No (formality examination only) | No (preliminary examination only) |
| Term | 20 years from filing | 10 years from filing | 15 years from filing |
| Time to grant | 18-22 months (average) | 6-10 months | 6-10 months |
| Inventive step standard | "Prominent substantive features and notable progress" | "Substantive features and progress" (lower bar) | Novelty and aesthetic distinctiveness |
| Annual fees | Escalating, from CNY 900/year | Escalating, from CNY 600/year | Escalating, from CNY 600/year |
Invention patents are the closest equivalent to US utility patents or European patents -- covering products and processes with a full substantive examination requirement.
Utility models are one of the most strategically important features of the Chinese system. They cover the shape or structure of a product (not processes), receive only a formality examination, and grant in roughly 6-10 months. The lower examination bar means they are easier to obtain but also easier to invalidate. Since 2009, CNIPA has required a patent evaluation report before a utility model can be enforced -- essentially a post-grant patentability assessment that courts require before issuing injunctions or awarding damages.
Design patents protect the aesthetic appearance of products. China's design patent system was strengthened in 2021, extending the term from 10 to 15 years and introducing partial designs. Design patents are examined for novelty and distinctiveness but skip the rigorous substantive examination applied to invention patents.
The Chinese Grant Procedure
The CNIPA patent granting procedure for invention patents follows a structured path from filing through examination to grant:
CNIPA invention patent grant procedure. Utility models and design patents skip substantive examination and proceed directly from formality examination to grant.
Several features of the Chinese procedure deserve attention:
Early publication. Invention patent applications are published 18 months after the filing date (or priority date), similar to the US and European systems. Applicants can request early publication, which is useful when provisional protection against infringers is needed.
Request for examination. Substantive examination is not automatic. The applicant must request examination within three years of the filing date. If no request is filed, the application is deemed withdrawn. This mirrors the Japanese and Korean systems and differs from the US system, where examination begins automatically.
Dual filing strategy. Many applicants file both an invention patent application and a utility model application for the same invention simultaneously. The utility model grants quickly (providing early enforceable rights), while the invention patent undergoes substantive examination for a stronger, longer-lasting right. If the invention patent is granted, the applicant must abandon the utility model to avoid double patenting.
Patent evaluation reports for utility models. Before enforcing a utility model in Chinese courts, the patent holder must obtain a patent evaluation report from CNIPA. This report assesses the novelty and inventive step of the utility model -- effectively performing the substantive examination that was skipped during prosecution. Courts will not accept enforcement actions for utility models without this report, and a negative evaluation report makes enforcement practically impossible. Factor the cost and time of obtaining this report (typically 2-4 months) into your utility model strategy.
China-Specific Strategic Considerations
Language. Applications must be filed in Chinese. If you are entering the national phase from a PCT application, translations must be filed within the 30-month deadline (extendable by 2 months with a surcharge). Translation quality is critical -- Chinese examiners work from the Chinese text, and translation errors can narrow claim scope or create added-matter issues.
Local agent requirement. Foreign applicants without a domicile or business office in China must appoint a qualified Chinese patent agent (attorney) to handle the prosecution. Direct representation is not permitted.
Absolute novelty. Like the EPO, China applies an absolute novelty standard -- public disclosure anywhere in the world before the filing or priority date destroys novelty. China does provide a limited 6-month grace period, but only for disclosures made at specified international exhibitions, academic or technical conferences recognized by the Chinese government, or unauthorized disclosures by third parties.
Japan (JPO)
The Japan Patent Office (JPO) receives approximately 300,000 patent applications annually and is one of the most respected examination authorities in the world. JPO examination is known for its thoroughness, consistency, and high quality, and a JPO-granted patent carries significant weight internationally.
Key Features of the Japanese System
| Feature | Detail |
|---|---|
| Patent types | Invention patent, utility model, design |
| Patent term | 20 years from filing (invention); 10 years from filing (utility model) |
| Examination trigger | Request for examination within 3 years of filing |
| Average first action | ~10 months after examination request |
| Average time to grant | ~14-15 months after examination request |
| Official languages | Japanese |
| Grace period | 12 months for inventor's own disclosure (with declaration) |
| Post-grant opposition | Available within 6 months of grant publication |
Request for Examination
Like China and South Korea, the JPO does not automatically examine patent applications. The applicant (or any third party) must file a request for examination within three years of the filing date. If no request is filed, the application is deemed withdrawn. This deferred system allows applicants to evaluate commercial potential before committing to examination costs -- approximately 75% of JPO applications proceed to examination, while 25% are voluntarily abandoned.
Examination Quality and Speed
After a request for examination is filed, the average time to a first office action is approximately 10 months, with total prosecution averaging 14-15 months. The JPO also offers several accelerated examination programs:
| Program | Eligibility | Timeline |
|---|---|---|
| Accelerated examination | Working the invention in Japan, or filing corresponding application abroad | First action in ~2-3 months |
| Super-accelerated examination | Working the invention in Japan AND corresponding foreign filing | First action in ~1 month |
| Patent Prosecution Highway (PPH) | Allowable claims in corresponding foreign application | First action in ~2-3 months |
| IP Acceleration Program for Startups | Small/medium enterprises, startups, universities | Prioritized examination |
The super-accelerated examination program is remarkable -- applicants who qualify can receive a first office action within approximately one month of filing the request. No other major patent office offers comparable speed.
Japanese Patent Numbering
Japanese patent numbering uses a system based on the Japanese era calendar (Nengou system), which can be confusing for foreign practitioners. Since 2000, Japan switched to Western calendar years for patent numbering, but documents filed before 2000 use era designations such as Heisei (H) or Showa (S). The current era is Reiwa, which began on 1 May 2019.
Patent publication numbers follow the format: JP [year]-[serial number] [kind code]. For example, JP 2024-123456 A indicates a published unexamined application from 2024.
Japan-Specific Strategic Considerations
Translation. Applications must be filed in Japanese. PCT national phase entry allows submission of the original PCT application language with a Japanese translation due within a specified period (typically 30 months from the priority date). As with China, translation quality is critical.
Divisional applications. Japan allows divisional applications to be filed at several points during prosecution, providing opportunities to pursue different claim scopes or respond to rejections. The rules on divisional filing windows are more flexible than in many other jurisdictions.
Claim fees. The JPO charges per-claim fees for both examination and annuities. This cost structure incentivizes applicants to file leaner claim sets than they might at the USPTO, where additional claim fees only kick in above 20 total claims and 3 independent claims. Consider your claim strategy carefully.
South Korea (KIPO)
The Korean Intellectual Property Office (KIPO) is the fastest patent-examining office among the IP5. Korean patent literature became part of the PCT minimum documentation in 2007, and KIPO has invested heavily in examination infrastructure and accelerated processing programs.
Key Features of the Korean System
| Feature | Detail |
|---|---|
| Patent types | Invention patent, utility model, design |
| Patent term | 20 years from filing (invention); 10 years from filing (utility model) |
| Examination trigger | Request for examination within 3 years of filing |
| Average first action | ~10-11 months (regular); ~2 months (super-fast track) |
| Official languages | Korean |
| Grace period | 12 months for inventor's own disclosure (with declaration) |
| Post-grant challenge | Invalidation trial at the Intellectual Property Trial and Appeal Board (IPTAB) |
Examination Speed: The Fastest in the World
KIPO offers three distinct examination tracks, and its fastest option is unmatched globally:
| Track | Average First Action | Requirements |
|---|---|---|
| Regular examination | ~10-11 months | Standard request for examination |
| Fast-track (prioritized) examination | ~4-5 months | Working the invention in Korea, SME applicant, green technology, or other qualifying criteria |
| Super-fast track | ~2 months | Invention being worked commercially AND prior consultation with examiner |
The super-fast track program produces first office actions in as little as two months. For companies that need granted patents quickly -- to support licensing negotiations, secure financing, or enforce rights -- KIPO's speed is a genuine competitive advantage. KIPO also participates actively in the Patent Prosecution Highway (PPH), allowing applicants with favorable results from another office to request expedited examination.
Korea-Specific Strategic Considerations
Technology focus. South Korea is a global leader in semiconductors, displays, telecommunications (5G/6G), batteries, and consumer electronics. If your inventions relate to these technology areas, Korean patent protection is particularly important because of the concentration of competitors, manufacturers, and supply chain participants in the Korean market.
Utility models. Like China and Japan, Korea offers utility model protection with a lower inventive step threshold and faster grant. Korean utility models have a 10-year term and can be useful for incremental innovations in product design and structure.
Cost efficiency. Korean patent prosecution costs are generally lower than in Japan, the US, or Europe. Official fees are modest, and local attorney costs are competitive. Combined with the fast examination timelines, Korea offers an attractive cost-benefit ratio for patent protection.
Post-grant proceedings. Korean patents can be challenged through invalidation trials before the Intellectual Property Trial and Appeal Board (IPTAB). These proceedings are relatively accessible and provide a mechanism for competitors to challenge weak patents.
India (IPO)
India's modern patent law dates to the Patents Act of 1970, significantly amended in 2005 to comply with the TRIPS Agreement. Filing volumes have grown rapidly -- from approximately 50,000 applications in 2018 to over 90,000 by 2024 -- and several features of the Indian system are genuinely unique.
Key Features of the Indian System
| Feature | Detail |
|---|---|
| Patent types | Invention patent only (no utility models, no design patents under the Patents Act) |
| Patent term | 20 years from filing (or PCT international filing date) |
| Examination trigger | Request for examination within 48 months of filing/priority date |
| Average time to grant | 3-5 years (improving, previously much longer) |
| Official languages | English and Hindi |
| Grace period | 12 months (limited to disclosures at government-recognized exhibitions or published in academic journals) |
| Post-grant challenge | Post-grant opposition within 12 months of grant publication |
Pre-Grant Opposition: A Unique Feature
India is one of the few major patent jurisdictions that provides a robust pre-grant opposition mechanism. Any person can file a representation opposing the grant of a patent application after it is published but before it is granted. The grounds for pre-grant opposition are broadly defined and include lack of novelty, lack of inventive step, non-patentable subject matter, insufficient disclosure, and others.
Pre-grant opposition has been actively used in India, particularly in the pharmaceutical sector, where generic manufacturers and public health organizations challenge patent applications on essential medicines before they are granted. India also provides for post-grant opposition, which must be filed within 12 months of the grant publication date.
Section 3(d): Pharmaceutical Restrictions
Section 3(d) of the Indian Patents Act provides that "the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance" is not patentable. This provision targets "evergreening" -- obtaining new patents on minor modifications to existing drugs to extend protection beyond the original patent term.
The landmark Supreme Court decision in Novartis AG v. Union of India (2013) upheld Section 3(d) and denied a patent for a crystalline form of imatinib mesylate (Gleevec/Glivec), confirming that India applies a higher bar for pharmaceutical patentability than most other jurisdictions.
Section 3(d) impacts pharmaceutical strategy. If you are filing pharmaceutical patents in India, be aware that new forms, derivatives, polymorphs, salts, and combinations of known substances require demonstration of enhanced therapeutic efficacy -- not just improved physical or chemical properties like better solubility or stability. Your Indian patent application should include comparative data showing enhanced efficacy wherever possible. This requirement does not apply in the US, Europe, Japan, China, or Korea, making India an outlier that requires specific drafting attention.
Compulsory Licensing
India has active compulsory licensing provisions under Sections 84 and 92 of the Patents Act. In 2012, India issued its first (and so far only) compulsory license, in Natco Pharma v. Bayer Corporation, for Bayer's kidney cancer drug sorafenib (Nexavar). The grounds included that the invention was not available at a reasonably affordable price and was not being worked in India. While only one compulsory license has been issued, the provisions remain a strategic consideration, particularly for pharmaceutical patents.
India-Specific Strategic Considerations
No utility model system. Only invention patents are available under the Patents Act. Design protection exists under a separate statute (the Designs Act, 2000).
Working requirement. Patent holders must file Form 27 (Statement of Working) annually, disclosing whether the patent is commercially worked in India. Non-working can be a ground for compulsory licensing -- a reporting requirement unique among major patent jurisdictions.
English language. Applications can be filed in English, a significant practical advantage over China, Japan, and Korea where translation is mandatory and costly.
Expedited examination. Available for DPIIT-recognized startups, small entities, female applicants, and applicants aged 60 or older. Expedited examination can reduce the time to first examination report to approximately 6-9 months.
Taiwan (TIPO)
Taiwan's Intellectual Property Office (TIPO) operates a patent system entirely separate from mainland China's CNIPA. Despite not being a member of the PCT, WIPO, or the Paris Convention, Taiwan maintains an advanced patent system critically important for the semiconductor and electronics industries.
Key Features of the Taiwanese System
| Feature | Detail |
|---|---|
| Patent types | Invention patent, utility model, design patent |
| Patent term | 20 years from filing (invention); 10 years from filing (utility model); 15 years from filing (design) |
| Examination trigger | Request for examination within 3 years of filing |
| Average time to grant | 18-24 months for invention patents |
| Official languages | Chinese (Traditional) |
| Grace period | 12 months for inventor's own disclosure |
| PCT member | No -- direct filing or priority claim required |
Separate System, Distinct Rules
Taiwan shares structural similarities with the Chinese, Japanese, and Korean systems -- it offers invention patents, utility models, and design patents, with a deferred examination system requiring a request within three years. However, several features are distinctive.
No PCT route. Because Taiwan is not a PCT member, applicants cannot enter the national phase from a PCT application. A separate national application must be filed directly at TIPO, claiming priority under Taiwan's domestic provisions. This requires separate tracking and is often overlooked in global filing strategies.
Priority claims. Taiwan recognizes priority claims from WTO member states and countries granting reciprocal recognition. Priority must be claimed within 12 months for invention and utility model applications, and 6 months for designs.
Technology importance. Taiwan is home to TSMC, MediaTek, Foxconn, and numerous other semiconductor and electronics companies. For inventions related to chip design, semiconductor manufacturing, and consumer electronics, Taiwan patent protection is strategically essential -- even though it is often underappreciated in global filing strategies focused on PCT jurisdictions.
Comparative Overview
The following table provides a side-by-side comparison of the five Asian patent jurisdictions covered in this chapter. Use it as a quick reference when making filing decisions.
| Factor | China (CNIPA) | Japan (JPO) | South Korea (KIPO) | India (IPO) | Taiwan (TIPO) |
|---|---|---|---|---|---|
| Annual filings | ~1,640,000 | ~300,000 | ~290,000 | ~90,000 | ~75,000 |
| Patent types | Invention, utility model, design | Invention, utility model, design | Invention, utility model, design | Invention only | Invention, utility model, design |
| Term (invention) | 20 years | 20 years | 20 years | 20 years | 20 years |
| Examination request deadline | 3 years | 3 years | 3 years | 48 months | 3 years |
| Average time to grant | 18-22 months | 14-15 months | 10-18 months | 3-5 years | 18-24 months |
| Fastest track | Priority exam (~6-12 months) | Super-accelerated (~1 month) | Super-fast track (~2 months) | Expedited (~6-9 months to first action) | Accelerated examination |
| PCT member | Yes | Yes | Yes | Yes | No |
| Official language | Chinese | Japanese | Korean | English/Hindi | Chinese (Traditional) |
| Grace period | 6 months (limited) | 12 months | 12 months | 12 months (limited) | 12 months |
| Utility models | Yes | Yes | Yes | No | Yes |
| Pre-grant opposition | No | No | No | Yes | No |
| Post-grant opposition | Invalidation request at CNIPA | Opposition within 6 months; invalidation trial | Invalidation trial at IPTAB | Post-grant opposition within 12 months | Invalidation action |
Annual Patent Filings by Asian Office (Thousands, 2024)
Working with Local Agents and Practical Considerations
All five Asian jurisdictions require foreign applicants to appoint a qualified local patent agent or attorney. You cannot represent yourself before CNIPA, JPO, KIPO, IPO, or TIPO without a domicile or place of business in the relevant jurisdiction.
Foreign Filing and Agent Requirements
| Jurisdiction | Agent Requirement | Language Requirement | Legalization/Notarization |
|---|---|---|---|
| China (CNIPA) | Mandatory Chinese patent agent | Chinese (Simplified) | Power of attorney required; notarization sometimes required for priority documents |
| Japan (JPO) | Mandatory patent attorney (Benrishi) | Japanese | No legalization required for most filings; power of attorney optional but recommended |
| South Korea (KIPO) | Mandatory Korean patent attorney (Byunrisa) | Korean | Power of attorney required; no apostille or legalization for most filings |
| India (IPO) | Mandatory Indian patent agent | English or Hindi | Power of attorney required; no notarization or legalization typically needed |
| Taiwan (TIPO) | Mandatory Taiwanese patent agent | Chinese (Traditional) | Power of attorney required; priority documents may require authentication |
Language and Translation
The single largest practical challenge when filing in China, Japan, South Korea, and Taiwan is translation. Patent translations require specialized technical vocabulary and precise legal language -- a mistranslation in the claims can narrow scope, create prosecution history estoppel, or introduce added matter that prevents amendment. Budget for high-quality patent translation from day one.
India's English-language advantage. India is the only major Asian patent jurisdiction where patent applications can be filed and prosecuted entirely in English. This eliminates translation costs and risks, making India one of the most accessible Asian offices for English-speaking applicants. If cost is a significant constraint in your filing strategy, India offers a lower barrier to entry than China, Japan, Korea, or Taiwan.
National Phase Entry Deadlines
For PCT applications entering the national phase in Asian jurisdictions, the deadlines are as follows:
| Jurisdiction | National Phase Deadline | Extension Available? |
|---|---|---|
| China (CNIPA) | 30 months from priority date | 2-month extension with surcharge |
| Japan (JPO) | 30 months from priority date | No standard extension; restoration possible in limited circumstances |
| South Korea (KIPO) | 31 months from priority date | No standard extension; restoration possible in limited circumstances |
| India (IPO) | 31 months from priority date | No standard extension; restoration possible in limited circumstances |
| Taiwan (TIPO) | Not applicable (not a PCT member) | N/A -- must file directly |
Taiwan requires a separate direct filing because it is outside the PCT system -- the single most common filing oversight for Asian patent portfolios. Flag it separately in your filing calendar.
Frequently Asked Questions
Filing Strategy
Procedures and Timelines
Practical Matters
What's Next
This chapter covered the major Asian patent offices -- CNIPA, JPO, KIPO, IPO, and TIPO -- and their distinct procedures, timelines, and strategic considerations. Chapter 16 brings it all together with multi-jurisdictional patent strategy: how to coordinate filings across the US, Europe, and Asia, manage costs, and build a coherent global patent portfolio.